FibroGen (NASDAQ:FGEN) +4.4% after-hours following news that the Food and Drug Administration accepted its New Drug Application for roxadustat for the treatment of anemia of chronic kidney disease.
The filing of the roxadustat NDA triggers a $50M milestone payment from AstraZeneca (NYSE:AZN) to FibroGen.
Roxadustat is the first orally administered small
molecule hypoxia-inducible factor prolyl hydroxylase inhibitor accepted
by the FDA for review for the treatment of anemia of CKD.
https://seekingalpha.com/news/3540861-fda-accepts-nda-for-fibrogen-anemia-treatment
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.